Evidence map›Paper›PMID 25472953›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2015

Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation.

Jingjing Zhang, Lili Ding, Baocan Wang, Gaiyan Ren, Aning Sun, Chao Deng, Xiaohui Wei, Sridhar Mani, Zhengtao Wang, Wei Dou

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Notoginsenoside R1 promotes Lgr5Acta pharmacologica Sinica · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Combination ofEvidence-based complementary and alternative medicine : eCAM · 2023
    Review
  10. Therapeutic effects ofBioengineered · 2022
    Article
  11. Role of Bile Acids and Nuclear Receptors in Acupuncture in Improving Crohn's Disease.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  12. Frontiers in pharmacology · 2022
    Article
  13. Antioxidant, Anticancer, and PXR-Dependent CYPOxidative medicine and cellular longevity · 2022
    Article
  14. Article
  15. Article
  16. St. John's Wort alleviates dextran sodium sulfate-induced colitis through pregnane X receptor-dependent NFκB antagonism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jingjing ZhangShanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C.D., X.W., Z.W., W.D.); Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.).
Lili DingShanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C.D., X.W., Z.W., W.D.); Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.).
Baocan WangShanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C.D., X.W., Z.W., W.D.); Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.).
Gaiyan RenShanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C.D., X.W., Z.W., W.D.); Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.).
Aning SunShanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C.D., X.W., Z.W., W.D.); Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.).
Chao DengShanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C.D., X.W., Z.W., W.D.); Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.).
Xiaohui WeiShanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C.D., X.W., Z.W., W.D.); Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.).
Sridhar ManiShanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C.D., X.W., Z.W., W.D.); Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.).
Zhengtao WangShanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C.D., X.W., Z.W., W.D.); Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.) wangzht@shutcm.edu.cn vivi.dou@yahoo.com.
Wei DouShanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C.D., X.W., Z.W., W.D.); Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.) wangzht@shutcm.edu.cn vivi.dou@yahoo.com.
Shanghai University of Traditional Chinese Medicine · CNAlbert Einstein College of Medicine · USXinHua Hospital · CN

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
Chemical Modulation of Orphan Nuclear Receptor FunctionR01CA127231 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI MANI, SRIDHAR · 2009 to 2014
$1.6M
NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA127231NCI NIH HHS R01-CA127231
6 · The paper itself

Abstract

Notoginsenoside R1 (R1) is the main bioactive component in Panax notoginseng, an old herb medicine widely used in Asian countries in the treatment of microcirculatory diseases. However, little is known about the effect of R1 on inflammatory bowel disease (IBD). The present study demonstrated that R1 alleviated the severity of dextran sulfate sodium-induced colitis in mice by decreasing the activity of myeloperoxidase, the production of cytokines, the expression of proinflammatory genes, and the phosphorylation of IκB kinase, IκBα, and p65 in the colon. Further studies indicated that R1 dose-dependently activated human/mouse pregnane X receptor (PXR), a known target for decreasing inflammation in IBD, and upregulated the expression of genes involved in xenobiotic metabolism in colorectal cells and the colon. Ligand pocket-filling mutant (S247W/C284W or S247W/C284W/S208W) of the human PXR abrogated the effect of R1 on PXR activation. Time-resolved fluorescence resonance energy transfer PXR competitive binding assay confirmed R1 (ligand) binding affinity. In addition, PXR overexpression inhibited nuclear factor-κB (NF-κB)-luciferase activity, which was potentiated by R1 treatment. PXR knockdown by small interfering RNA demonstrated the necessity of PXR in R1-induced upregulation of the expression of xenobiotic-metabolizing enzymes and downregulation of NF-κB activity. Finally, the anti-inflammatory effect of R1 was confirmed in trinitrobenzene sulfonic acid-induced colitis in mice. These findings suggest that R1 attenuates experimental IBD possibly via the activation of intestinal PXR signaling.

Indexed as

AnimalsAnti-Inflammatory AgentsColonDisease Models, AnimalFemaleGene ExpressionGinsenosidesHT29 CellsHumansInflammatory Bowel DiseasesInterleukin-6Mice, Inbred C57BLNF-kappa BPeroxidasePregnane X ReceptorReceptors, SteroidAnti-Inflammatory AgentsGinsenosidesInterleukin-6NF-kappa Bnotoginsenoside R1PeroxidasePregnane X ReceptorReceptors, SteroidTumor Necrosis Factor-alpha

Identifiers

PMID25472953
PMCPMC4293438
OpenAlexW2098568145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.